Skip to content

Search

Funding boost to help turn research into practical change

Research projects sharing in a $2.1 million funding boost will seek to translate research findings into changes that benefit patients and help the health system run more efficiently.

Biobank funding supports valuable research resources

Four The Kids Research Institute Australia-based biobanks which underpin a range of cancer, respiratory and early life research have received more than $450,000 in funding.

The Kids respiratory researcher wins prestigious prize at 2021 Premier’s Science Awards

The Kids Research Institute Australia researcher, Niamh Troy, has been named a joint winner of the Exxon Mobile Student Scientist of the Year award at the Premier’s Science Awards.

Bushfires: Tips to protect family from smoke exposure

Perth’s north-east is under threat from an out-of-control bushfire.

World-first study shows increased atmospheric CO2 levels damage young lungs

Australian researchers who have conducted the first study looking at the direct health impacts of predicted carbon dioxide levels say the results are worrying and highlight the urgent need for more research into the issue.

WA researchers lead global centre to eliminate childhood asthma

An ambitious project that could stop children developing asthma is the centrepiece of a new world-class respiratory research centre launched in Perth.

Could Perth lakes hold the secret to fighting antibiotic-resistant superbugs?

Perth researchers have discovered a predatory virus living in the city’s lakes and rivers that can fight antibiotic-resistant superbugs in children.

Pre-term kids get green light to exercise

Parents of children born prematurely have expressed concerns about their child’s lung health when they exercise, with symptoms such as breathlessness.

Unravelling the respiratory health path across the lifespan for survivors of preterm birth

Many survivors of preterm birth will have abnormal lung development, reduced peak lung function and, potentially, an increased rate of physiological lung function decline, each of which places them at increased risk of chronic obstructive pulmonary disease across the lifespan. 

A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections

Current treatments for respiratory infections are severely limited. Ethanol's unique properties including antimicrobial, immunomodulatory, and surfactant-like activity make it a promising candidate treatment for respiratory infections if it can be delivered safely to the airway by inhalation. Here, we explore the safety, tolerability, and pharmacokinetics of inhaled ethanol in a phase I clinical trial.